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Abstract
Migration of immune cells to the target organ plays a key role in autoimmune disorders like multiple sclerosis (MS).
However, the exact underlying mechanisms of this active process during autoimmune lesion pathogenesis remain elusive.
To test if pro-inflammatory and regulatory T cells migrate via a similar molecular mechanism, we analyzed the expression of
different adhesion molecules, as well as the composition of infiltrating T cells in an in vivo model of MS, adoptive transfer
experimental autoimmune encephalomyelitis in rats. We found that the upregulation of ICAM-I and VCAM-I parallels the
development of clinical disease onset, but persists on elevated levels also in the phase of clinical remission. However, the
composition of infiltrating T cells found in the developing versus resolving lesion phase changed over time, containing
increased numbers of regulatory T cells (FoxP3) only in the phase of clinical remission. In order to test the relevance of the
expression of cell adhesion molecules, animals were treated with purified antibodies to ICAM-I and VCAM-I either in the
phase of active disease or in early remission. Treatment with a blocking ICAM-I antibody in the phase of disease progression
led to a milder disease course. However, administration during early clinical remission aggravates clinical symptoms.
Treatment with anti-VCAM-I at different timepoints had no significant effect on the disease course. In summary, our results
indicate that adhesion molecules are not only important for capture and migration of pro-inflammatory T cells into the
central nervous system, but also permit access of anti-inflammatory cells, such as regulatory T cells. Therefore it is likely to
assume that intervention at the blood brain barrier is time dependent and could result in different therapeutic outcomes
depending on the phase of CNS lesion development.
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Introduction
Thymus-derived (naturally occurring) regulatory T cells (Treg)
are essential for regulating peripheral autoimmune tolerance and
thereby inflammation in the context of infection, autoimmunity
and transplant rejection [1]. It has been demonstrated that
antigen-specific Treg have the capacity of limiting autoimmune
tissue damage in disease models for multiple sclerosis, rheumatoid
arthritis and type I diabetes [2,3,4,5,6,7].
In vitro, natural Treg are hypoproliferative and suppress T effector
cell (Teff) under autologous and alloreactive coculture conditions
[8,9]. Conceptually Treg influence physiological and pathological
immune reactions at different levels, thereby influencing parenchy-
mal immune homeostasis. One concept assumes that Treg are
equipped with a higher propensity to migrate in order to prevent
Teff at target sites of emerging inflammation [10]. However, the
origin and temporal pattern of Treg actions in acute and chronic
autoimmune tissue inflammation in vivo is still largely elusive.
It has been proposed that in a model of MS, experimental
autoimmune encephalomyelitis (EAE) Treg are unable to reach the
central nervous system (CNS), but prevent migration of autore-
active Teff into the target organ [3]. More recent reports, however,
demonstrate that Treg accumulate within the murine CNS during
EAE [4] and limit EAE relapses in the CNS [11,12]. However, the
underlying mechanism of Treg migration to the target organ
during CNS lesion development remains largely unknown.
In general, cell trafficking to the CNS is a highly regulated
process and involves different components on both interacting
compartments – T cells and the blood brain barrier (BBB) [13,14].
Under physiological conditions, highly specialized brain endothe-
lial cells are key components that limit trans- and paracellular
movement of molecules and cells [13]. Under inflammatory
conditions, however, structural integrity of the BBB seems to
collapse and transendothelial trafficking increases [13,14,15]. The
involvement of various chemokines, as well as the expression of
cellular adhesion molecules and tight junction proteins has been
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alpha4beta1 integrin very late antigen (VLA)-4 and leukocyte
function associated antigen (LFA)-1 with their respective immu-
noglobulin-like ligands vascular cell adhesion molecule (VCAM)-I
and intercellular adhesion molecule (ICAM)-I were shown to be
essential for leukocyte adhesion and migration into the CNS in vivo
[14,16,17,18]. Similar mechanisms were described to play a role
for the migration of Teff in EAE [17,19,20,21].
To test if these molecular mechanisms are also involved in the
regulation of Treg migration in an in vivo model of autoimmune
inflammation, we performed adoptive transfer (AT)-EAE in rats.
This model is considered to be in particular useful to evaluate the
infiltration of leukocytes into the CNS [22,23] and opens up a




All animal experiments were approved and conducted in
accordance with the laws and regulations of the regulatory
authorities for animal care and use in Lower Franconia, Germany
(ID 55.2-2531.01-75/07). 6–8 week old female Lewis rats with body
weights ranging from 140–160 g were purchased from Harlan
(Harlan Winkelmann, Borchen, Germany). AT-EAE was induced
by intravenous injection of freshly activated myelin basic protein
(MBP)-specific T cell blasts, using a dose of 8610
6 T cells
respectively to generate EAE. Animals were weighed and their
disease state was scored by two blinded examiner (SD, SGM)
according to clinical signs. This score ranged from 0 to 10; scores
were as follows: 0=normal; 1=limp tail, impaired righting; 2=gait
ataxia; 3=moderate paraparesis; 4=tetraparesis; 5=death.
For blocking experiments animals were injected i.p. with 1 mg
of a monoclonal murine antibody against rat-ICAM-I (clone 1A-
29, BD Biosciences, Heidelberg, Germany) and 1.5 mg of a
monoclonal antibody against rat-VCAM-I (clone MR106,
eBioscience, San Diego, CA) in a volume of 1 ml PBS i.p.
Sham-treated animals received 1 ml PBS only, EAE controls were
untreated.
Preparation of microparticles
Poly(butyl-2-cyanoacrylate) (PBCA) stabilized air-filled micropar-
ticles were generated and used as described earlier [24,25]. The
target-specificity of streptavidin loaded microparticles was generated
immediately prior to their use by adding either 50 mg biotinylated
anti-rat-ICAM-I- (clone 1A-29, BD Biosciences) or anti-rat-VCAM-
I- (clone MR106, eBioscience) antibodies to a suspension containing
5610
8 microparticles (10 min incubation time).
Immunocytochemistry
Native brains and spinals cord were prepared at the respective
time points and snap-frozen at 270uC. Immunohistochemistry
was performed on 10 mm cryosections according to standard
protocols with a mouse anti-rat-ICAM-I- antibody (clone 1A-29,
BD Biosciences, 1:100), anti-rat-VCAM-I- antibody (clone
MR106, eBiosciences, 1:100), mouse anti-rat-CD4- (clone 15-
8A2, Holland Biotechnology bv, Rotterdam, Netherlands, 1:8000),
mouse anti-rat-CD8- (clone R1-10B5, Seikagaku Kogyo co.,
Tokyo, Japan, 1:100), and anti-rat-FoxP3 (clone 150D, biolegend,
SanDiego, CA, 1:500). Specificity of staining was confirmed by
omitting the primary antibody as a negative control. After
blocking endogenous peroxidase activity with 3% H2O2 and
0.2 M sodium azide in methanol, primary antibodies were
detected using the ABC system (DAKO, Hamburg, Germany)
with 3,39-diaminobenzidine tetrahydrochloride as substrate. All
sections were counterstained with haematoxylin for 30 s, dehy-
drated and mounted in Vitro-cludH (R. Langenbrinck, Emmen-
dingen, Germany). Quantitative analysis of inflammatory infil-
trates within the spinal cord was performed as previously described
[26]. Briefly, an average of 10 spinal cord cross-sections (cervical,
thoracic and lumbal, respectively) from 4–8 rats per timepoint
were used for evaluation. Complete sections were counted by
blinded observers and cells were calculated as cells per slide.
Flow cytometry
Quantitative analysis of CNS infiltrates during AT-EAE by flow
cytometry was done during disease progression, at disease
maximum and during early remission using a method described
by Magnus et al., 2005 [27]. Briefly, rats were sacrificed with CO2
and spinal cords were flushed out of the spinal column with sterile
PBS, the brain was prepared and used in toto. CNS tissue was
homogenized and strained through a 70 mm nylon filter (BD
Biosciences). After centrifugation, the cell pellet was resuspended
in 9 ml Percoll and mixed with 20 ml PBS. The gradient was
centrifuged at 600 g for 25 min at room temperature (21 to 23uC).
The interphase cells were collected and washed before staining.
Spleens were washed in PBS and homogenized by pressing
through a 40 mm cell strainer. After washing, splenocytes were
separated by gradient centrifugation. Cells were counted and
diluted to a concentration of 20610
6 splenocytes/ml in FACS
buffer (made from PBS, 1% FCS and 0.1% sodium acide). For
flow cytometry, cells were stained with the following directly
labelled antibodies for 30 min at 4uC: CD3, CD4, CD8, CD25
and CD28 and their respective isotype antibodies (all BD
Biosciences). FoxP3 staining was performed according to the
manufacturer’s instructions for intracellular staining using a FoxP3
anti-rat staining kit (clone: FJK-16s; eBioscience). Specific staining
was assessed by applying accordant isotype control antibodies.
Cells were washed and analyzed using a FACSCalibur (FACS
calibur, BD Biosciences) with CellQuest software.
Statistical analysis
The experimental results are expressed as means +/2 standard
deviation. Significant differences between experimental groups
were analysed by using a t-test modified for small samples for
parametric data or Mann-Whitney U test for non-parametric
datasets. A p value of ,0.05 was considered statistically significant.
The statistical Software used was Statistica 3.0 (Statsoft, Tulsa,
OK, USA).
Results
Cellular composition of inflammatory CNS lesions over
time: evidence for the presence of CD4CD25FoxP3
regulatory cells in the remission phase of the disease
AT-EAE induced animals showed the first clinical symptoms
,72 hours after cell transfer. Disease progression thereafter is
rapid, leading to the peak of the disease ,96 h post cell injection
(Figure 1A). Improvement of clinical signs began 96–110 hours
after cell transfer (in the following also named early remission).
Usually the recovery phase lasted 48–72 hours (in the following
named late remission), approximately 240 hours after cell transfer
animals showed completely recovery (full remission; Figure 1A).
In a first step, we analyzed the cellular composition of the
inflammatory CNS lesions in AT-EAE at different time points.
Quantitative analysis of infiltrating immune cells by flow
cytometry analysis from homogenized CNS (brain and spinal
cord; Figure 1B) displayed high amounts of CD4 T cells within
Regulatory T Cells and Migrationregulatory
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Interestingly, the CD4 T cell population persisted also in the
stages of early clinical remission (Figure 1B). A percentage of
approximately 10% CD8 T cells could be observed throughout the
disease course (despite the fact that pure CD4-MBP-specific blasts
have been injected into mice) (Figure 1B). These results could be
confirmed using immunohistochemistry (Figure 1C). In contrast,
at disease maximum and even more pronounced in stages of early
clinical remission a significant increase of FoxP3+ expressing Treg
was notable (Figure 1D, E). Performing immunohistochemistry,
Treg could hardly be detected on serial sections during the phase of
disease progression (data not shown). To confirm these histopath-
ological findings, flow cytometry analysis from homogenized CNS
(brain and spinal cord) was performed (Figure 1F). As a positive
control, Treg were also identified within the spleen of AT-EAE
animals. The rates of Treg within the spleen were comparable to
the numbers known from the literature [28]. Flow cytometry
analysis data corroborated immunohistochemistry showing virtu-
ally no FoxP3 cells during disease progression in the CNS of the
animals, but a constant increase of regulatory cells from disease
maximum to stages of early clinical remission (Figure 1F)
indicating their important role in regulating the resolution phase
of the CNS immune responses.
Time course of adhesion molecule expression in EAE:
persisting expression of ICAM-I and VCAM-I during
disease remission
In a next step we investigated some main components involved
in the regulation of leukocyte trafficking. Therefore we analyzed
Figure 1. Migration of Teff and Treg in AT-EAE. (A) Clinical course of AT-EAE (n=8). (B) CD4 T cells are the predominant cell type within the CNS.
Both numbers of CD3CD4 (black bars) and CD3CD8 T cells (grey bars) are slightly increasing after 96 hours at the disease maximum (max) compared
with the progression stage (prog), but show persistence in the CNS when clinical symptoms are already remitting (early remission). (C) Quantitative
analysis of CD4 positive profiles in frozen spinal cord sections shows an increase of CD4 infiltrates to the time point of disease maximum. Persistence
of CD4 cells in early clinical remission (120 h) is also found on the histological level. (D) Quantification of FoxP3 immunoreactive cells in the spinal
cord of EAE animals were almost absent during disease progression (prog), but show a significant increase during the clinical maximum (max) and
were even more prominent in the stages of early clinical remission. (E) Representative immunostaining of lumbar spinal cord cryosections with
antibodies to FoxP3 demonstrates the presence of FoxP3 immunoreactive cells in EAE lesions (arrows). (F) Quantification of CD4FoxP3 positive cells in
the CNS over time by flow cytometry. CD4FoxP3 positive cells (grey bars) show an increase in early clinical remission compared to the clinical
maximum and the progression state where FoxP3 Treg could not be detected at all. CD4FoxP3 splenocytes (black bars) served as positive control.
Values represent clinical score means 6 SEM. ** p,0.01, * p,0.05
doi:10.1371/journal.pone.0015478.g001
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baseline (0 h) and 6 h, 72 h, 120 h, 168 h and 240 h after cell
transfer by using ICAM-I and VCAM-I specific microparticles for
ultrasound-based molecular imaging allowing serial analysis.
These microparticles mark ICAM-I and VCAM-I at the BBB
with the stimulated acoustic emission (SAE) effect, generating a
characteristic imaging pattern with a strong periventricular signal,
as well as a strong signal of the cerebellar and brain stem region
(Figure 2A).
For in vivo imaging of living anesthetized animals, the
periventricular signal was quantified by using the SPAQ
technology and the signal strength that correlates with the amount
of adhesion molecules, was expressed as acoustical counts (AC).
Within the course of AT-EAE, the molecular expression of
ICAM-I and VCAM-I changed parallel to the development of
clinical signs and symptoms (Figure 2B). Interestingly, in the
phase of clinical remission, expression levels only of VCAM-I
showed a slow decline to baseline similar to the clinical course,
whereas ICAM-I stayed up-regulated also during the stages of
early clinical remission (n=5; p=0.0415). After ,240 h expres-
sion pattern of both adhesion molecules returned to baseline levels.
In order to confirm our kinetic in vivo imaging ultrasound results,
we performed an immunocytochemical analysis of ICAM-I and
VCAM-I expression within the brain of AT-EAE animals at
different time points (Figure 2C). In the preclinical stage, ICAM-I
and VCAM-I could be detected, but the expression was low in
comparison to the expression pattern detected at disease
maximum (96 h). In accordance with our imaging results, the
strong expression pattern for ICAM-I persisted also in the stages of
early clinical remission (120 h). A reduction of the perivascular
Figure 2. Imaging of ICAM-I and VCAM-I temporal expression pattern during AT-EAE with the SPAQ technology. (A) The left panel
shows an AT-EAE rat brain with corresponding images of the brainstem, midbrain and frontal cortex. The yellow spots represent the SAE effect that is
generated by ICAM-I specific microparticles. The SAE signal is predominantly derived from the cerebellum/brainstem and the periventricular region.
Corresponding histological sections are shown. A strong vascular ICAM-I expression (arrows) can be observed. (B) Ultrasound derived sequential
quantification of ICAM-I and VCAM-I expression in AT-EAE shown as acoustical counts in relation to the clinical course. Both ICAM-I and VCAM-I are
upregulated in parallel to the clinical disease course and show a delayed return to baseline level in the clinical remission. (C) Serial
immunohistochemistry stainings with antibodies to ICAM-I and VCAM-I of periventricular brain cryosections 48 h (progression), 96 h (maximum),
120 h (early remission) and 168 h (late remission) after induction of EAE. Arrowheads demonstrate the ICAM-I and VCAM-I immunostaining at the
cerebral vessels. Representative examples are shown. Scale bar represents 500 mm. Values represent clinical score means 6 SD. *p,0.05.
doi:10.1371/journal.pone.0015478.g002
Regulatory T Cells and Migrationregulatory
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clinical remission (168 h) when the animals already showed full
recovery (Figure 2C).
Time dependence of adhesion molecule blockade with
antibodies to ICAM-I
As adhesion molecule expression stayed elevated during early
clinical remission, we analyzed if the constant up-regulation of
adhesion molecules in AT-EAE can not only influence the
migratory capacity of Teff, but also represent a relevant
mechanism to allow Treg to enter the CNS. To elucidate
the possible impact and time-dependence of cell adhesion
molecule expression at the BBB, we performed in vivo inhibition
experiments.
Therefore, AT-EAE animals were treated with a high dose of
purified monoclonal antibodies to ICAM-I, either in the phase of
disease progression or in early clinical remission. The administra-
tion of 1 mg anti-ICAM-I antibody during the phase of disease
progression resulted in a significant suppression of EAE in
comparison to sham-treated animals (Figure 3A). In contrast
however, the administration of anti-ICAM-I in the phase of early
clinical remission resulted in a short but notable aggravation of
clinical symptoms (Figure 3B). These data suggest that
prevention of ICAM-I-mediated T-cell CNS entry has phase
dependent consequences for the development or resolution of
CNS lesions. Aggravation of clinical symptoms after ICAM-
blockade in the early remission phase correlated with the phase of
FoxP3 Treg entry into the CNS.
Of note, using a blocking anti-VCAM-I antibody both during
the phase of disease progression and during early clinical remission
showed no significant effect on the clinical course of AT-EAE
(Figure S1) and no marked changes in whole brain FACS analysis
of CD4 and FoxP3 cell populations.
Taken together, our blocking experiments indicate an important
role for ICAM-I in terms of CNS trafficking of both inflammatory
Teff cells and Treg.
Discussion
To test if pro-inflammatory and regulatory T cells migrate via a
similar molecular mechanism, we analyzed the expression pattern
of ICAM-I and VCAM-I, as well as the composition of infiltrating
T cells in AT-EAE in rats. Whereas VCAM-I parallels the clinical
course, ICAM-I remained upregulated in the phase of early
clinical remission. However, the composition of infiltrating T cells
found in the developing versus resolving lesion phase changed over
time, containing increased numbers of Treg in the phase of clinical
remission.
In order to test the relevance of the expression of cell adhesion
molecules, animals were treated with purified antibodies to ICAM-
I and VCAM-I either in the phase of active disease or in early
remission. While treatment with a blocking ICAM-I antibody in
the phase of disease progression led to a milder disease course,
administration during early clinical remission aggravates clinical
symptoms. Treatment with anti-VCAM-I at different timepoints
had no significant effect on the disease course.
During inflammatory diseases of the CNS such as MS or its
prototype animal model EAE, the BBB has an active role in
regulating cell entry into the target organ and is characterized by
enhanced expression of traffic signals like adhesion molecules and
chemokines [14]. If distinct mechanisms play a role for specific T
cell subsets is not known so far. Thus, knowledge on the molecular
mechanisms involved in cell-type specific migration across the
BBB is not only important for our understanding of the
pathogenesis of autoimmune inflammation of the CNS, but can
also be relevant for the development or understanding of
treatments acting at the BBB.
Intensive research during the last decade has pointed to a
unique interaction of activated T cells with the BBB. By using
intravital fluorescence videomicroscopy in the EAE model, it was
shown that initial capture and subsequent firm adhesion of
activated T cells to the brain endothelium is mediated by an
interaction between VLA-4 and VCAM-I [21] while the
interaction between LFA-1 and its ligand ICAM-I on brain
endothelial cells is important for transmigration of activated cells
into the CNS [19]. Although these results have clarified the
distinct molecular interactions at the BBB, little is known about the
temporal regulation pattern of these important cell adhesion
molecules during the entire course of AT-EAE. We here used our
newly developed ultrasound-based molecular imaging and quan-
tification method SPAQ [24,25] addressing this important
question of temporal ICAM-I and VCAM-I expression in a serial
manner. These data were corroborated with more conventional
assessments of animal groups assessed by immunohistochemistry
and CNS flow cytometry analysis. These data showed up-
regulation of ICAM-I and VCAM-I that already preceded the
Figure 3. Time dependency of ICAM-I blockade at the BBB with
monoclonal antibodies in AT-EAE. Clinical courses of anti-ICAM-I
treated, sham treated and non treated animals are shown. Time points
of injection are marked with an arrow. (A) I.v. administration of 1 mg
anti-ICAM-I monoclonal antibodies in the clinical progression phase
(80 h after induction) results in a significant reduction of disease
severity in mAB treated animals compared to PBS treated and non
treated control animals. (B) Blocking of ICAM-I by mAB in the early
remission phase (105 h after induction) leads to a significant increase in
disease severity in mAB treated animals in comparison to PBS treated
and non treated animals, respectively. n=8 per group. Values represent
clinical score means 6 SD. *p,0.05.
doi:10.1371/journal.pone.0015478.g003
Regulatory T Cells and Migrationregulatory
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of clinical disease. However, only VCAM-I slowly returned to its
baseline parallel to clinical recovery, whereas ICAM-I showed an
increase during the stages of early clinical remission.
This suggested that BBB activation and cellular transmigration
is necessary also for immune cells actively participating in
counterbalancing or terminating proinflammatory Teff responses.
By analysing the cellular composition of the inflammatory CNS
lesions, we discovered that Treg become detectable in the
respective stage of early clinical remission, while they are absent
in the progression phase or under normal conditions, indicating
that persisting adhesion molecule expression might also allow
transmigration of these suppressive immune cell components. This
regulatory cell population has the potential to directly or indirectly
alter the activation and differentiation of pathogenic T cells [29].
There is evidence that Treg in the CNS provide beneficial effects in
neuroinflammation and the contribution of Treg in recovery and
protection from autoimmune encephalomyelitis has been demon-
strated [7,30]. There is also accumulating data in humans to
support the assumption that regulatory T cell populations
specifically migrate or accumulate in the CNS compartment, in
order to combat inflammation [31,32,33]. However, there is still
some controversial debate where exactly Treg modulate the
inflammatory response. Using the monoclonal anti-CD28 anti-
body JJ316 that induces Treg, Tischner et al. argue that Treg cell
action on Teff is mainly confined to the secondary lymphoid
organs. However, the authors did find Treg within the spinal cord
on day six after disease induction and suggested that Treg might
also play an additional role at sites of inflammation, e.g. in the
resolution of ongoing autoimmune diseases or in preventing
relapses [34].
As a proof of concept we here provide experiments in which we
applied high doses of a blocking anti-ICAM-I monoclonal
antibody at different time points. While an early administration
of the antibody during the stage of disease progression resulted in a
significant amelioration of the clinical disease, a subsequent
application of these blocking antibodies in the stage of early
clinical remission resulted in a clinical deterioration of the treated
animals. As our first analyses show that in our model Treg migrate
to the CNS to a later timepoint, it can be assumed that this short
term aggravation of the clinical symptoms might be due to the
prevention of counterregulatory or protective immune cells
recruited into the CNS, such as Treg. This result is very much
compatible with a concept assuming that Treg also act at the blood
brain barrier or within the parenchyma to counterbalance
inflammation.
Although our experiments thus far do not present direct
experimental evidence, it is suggestive that interaction of LFA-1/
ICAM-I but not VLA-4/VCAM-I is necessary for Treg to enter
the CNS, at least under the given experimental conditions. This
assumption is corroborated by recent findings that Treg express
comparable levels of LFA-1 und VLA-4 as Teff [35]. It is tempting
to speculate that molecular interactions between pro-inflammatory
and Treg and the BBB, namely that both pro-inflammatory and
Treg use ICAM-I for transmigration into the CNS. However, we
suppose that these interactions between different T cell subsets and
the BBB occur at different time points in the course of EAE.
According to these observations we assume that the outcome of
therapeutic interventions at the BBB is time dependent. Our
hypothesis might be an explanation of the conflicting results
published on the treatment of EAE with anti-ICAM-I antibodies.
While some studies including a study from the Wuerzburg group
could show a clear beneficial treatment effect [36,37]. Others
however could not reproduce this positive effect but show rather a
worsening of the disease [38,39].
Our data also have important implications for understanding
current therapeutic approaches acting at the BBB. There is no
doubt that we hold powerful drugs that can block transmigration
of inflammatory cells into the CNS to a great extent [40,41].
However, the timepoint of treatment seems to be important, as
unselective blockade of adhesion molecules at the BBB, not only
reduce trafficking of encephalitogenic Teff, but also avoid the
migration of Treg that could limit CNS lesion development or be
required for CNS immune surveillance.
In summary, our results indicate that adhesion molecules are
not only important for capture and migration of pro-inflammatory
T cells into the central nervous system, but also permit access of
anti-inflammatory cells, such as regulatory T cells. Therefore it is
likely to assume that intervention at the blood brain barrier is time
dependent and could result in different therapeutic outcomes
depending on the phase of CNS lesion development.
Supporting Information
Figure S1 No influence of VCAM-I inhibition on the
clinical course of AT-EAE. Clinical courses of anti-VCAM-I
treated (early and late intervention) and non treated animals are
shown. Phases of treatment are indicated in green (early
intervention) and red (late intervention). I.v. administration of
1.5 mg/kg anti-VCAM-I monoclonal antibodies in the clinical
progression phase (2d after induction) as well as in the early
remission phase (105 h after induction) has no influence on the
disease severity. N=8 per group. Values represent clinical score
means 6 SD.
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